Cargando…

Broad-Spectrum Anticancer Activity and Pharmacokinetic Properties of a Prenyloxy-Substituted Indeno[1,2-b]indole Derivative, Discovered as CK2 Inhibitor

Protein kinase CK2 is involved in regulating cellular processes, such as cell cycle, proliferation, migration, and apoptosis, making it an attractive anticancer target. We previously described a prenyloxy-substituted indeno[1,2-b]indole (5-isopropyl-4-(3-methylbut-2-enyloxy)-5,6,7,8-tetrahydroindeno...

Descripción completa

Detalles Bibliográficos
Autores principales: El-Awaad, Ehab, Birus, Robin, Marminon, Christelle, Bouaziz, Zouhair, Ballentin, Laurens, Aichele, Dagmar, Le Borgne, Marc, Jose, Joachim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226678/
https://www.ncbi.nlm.nih.gov/pubmed/34198928
http://dx.doi.org/10.3390/ph14060542
_version_ 1783712344079073280
author El-Awaad, Ehab
Birus, Robin
Marminon, Christelle
Bouaziz, Zouhair
Ballentin, Laurens
Aichele, Dagmar
Le Borgne, Marc
Jose, Joachim
author_facet El-Awaad, Ehab
Birus, Robin
Marminon, Christelle
Bouaziz, Zouhair
Ballentin, Laurens
Aichele, Dagmar
Le Borgne, Marc
Jose, Joachim
author_sort El-Awaad, Ehab
collection PubMed
description Protein kinase CK2 is involved in regulating cellular processes, such as cell cycle, proliferation, migration, and apoptosis, making it an attractive anticancer target. We previously described a prenyloxy-substituted indeno[1,2-b]indole (5-isopropyl-4-(3-methylbut-2-enyloxy)-5,6,7,8-tetrahydroindeno[1,2-b]indole-9,10-dione (4p)) as a very potent inhibitor of CK2 holoenzyme (IC(50) = 25 nM). Here, we report the broad-spectrum anticancer activity of 4p and provide substantial progress on its pharmacokinetic properties. Using a cell-based CK2 activity assay and live-cell imaging of cultured A431, A549, and LNCaP cancer cell lines, cellular CK2 target engagement was shown as well as strong antiproliferative, anti-migratory and apoptosis-inducing effects of 4p. Furthermore, evidence was found for the ability of 4p to disrupt A549 spheroid cohesion. A series of LC-MS/MS experiments revealed high and rapid cellular uptake (intracellular concentration is approximately 5 µM after 1 h incubation) and low metabolic stability of 4p. These results point to the value of 4p as a potent CK2 inhibitor with promising anticancer activities and should trigger future medicinal chemistry efforts to improve the drug-like properties of this compound.
format Online
Article
Text
id pubmed-8226678
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82266782021-06-26 Broad-Spectrum Anticancer Activity and Pharmacokinetic Properties of a Prenyloxy-Substituted Indeno[1,2-b]indole Derivative, Discovered as CK2 Inhibitor El-Awaad, Ehab Birus, Robin Marminon, Christelle Bouaziz, Zouhair Ballentin, Laurens Aichele, Dagmar Le Borgne, Marc Jose, Joachim Pharmaceuticals (Basel) Article Protein kinase CK2 is involved in regulating cellular processes, such as cell cycle, proliferation, migration, and apoptosis, making it an attractive anticancer target. We previously described a prenyloxy-substituted indeno[1,2-b]indole (5-isopropyl-4-(3-methylbut-2-enyloxy)-5,6,7,8-tetrahydroindeno[1,2-b]indole-9,10-dione (4p)) as a very potent inhibitor of CK2 holoenzyme (IC(50) = 25 nM). Here, we report the broad-spectrum anticancer activity of 4p and provide substantial progress on its pharmacokinetic properties. Using a cell-based CK2 activity assay and live-cell imaging of cultured A431, A549, and LNCaP cancer cell lines, cellular CK2 target engagement was shown as well as strong antiproliferative, anti-migratory and apoptosis-inducing effects of 4p. Furthermore, evidence was found for the ability of 4p to disrupt A549 spheroid cohesion. A series of LC-MS/MS experiments revealed high and rapid cellular uptake (intracellular concentration is approximately 5 µM after 1 h incubation) and low metabolic stability of 4p. These results point to the value of 4p as a potent CK2 inhibitor with promising anticancer activities and should trigger future medicinal chemistry efforts to improve the drug-like properties of this compound. MDPI 2021-06-05 /pmc/articles/PMC8226678/ /pubmed/34198928 http://dx.doi.org/10.3390/ph14060542 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
El-Awaad, Ehab
Birus, Robin
Marminon, Christelle
Bouaziz, Zouhair
Ballentin, Laurens
Aichele, Dagmar
Le Borgne, Marc
Jose, Joachim
Broad-Spectrum Anticancer Activity and Pharmacokinetic Properties of a Prenyloxy-Substituted Indeno[1,2-b]indole Derivative, Discovered as CK2 Inhibitor
title Broad-Spectrum Anticancer Activity and Pharmacokinetic Properties of a Prenyloxy-Substituted Indeno[1,2-b]indole Derivative, Discovered as CK2 Inhibitor
title_full Broad-Spectrum Anticancer Activity and Pharmacokinetic Properties of a Prenyloxy-Substituted Indeno[1,2-b]indole Derivative, Discovered as CK2 Inhibitor
title_fullStr Broad-Spectrum Anticancer Activity and Pharmacokinetic Properties of a Prenyloxy-Substituted Indeno[1,2-b]indole Derivative, Discovered as CK2 Inhibitor
title_full_unstemmed Broad-Spectrum Anticancer Activity and Pharmacokinetic Properties of a Prenyloxy-Substituted Indeno[1,2-b]indole Derivative, Discovered as CK2 Inhibitor
title_short Broad-Spectrum Anticancer Activity and Pharmacokinetic Properties of a Prenyloxy-Substituted Indeno[1,2-b]indole Derivative, Discovered as CK2 Inhibitor
title_sort broad-spectrum anticancer activity and pharmacokinetic properties of a prenyloxy-substituted indeno[1,2-b]indole derivative, discovered as ck2 inhibitor
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226678/
https://www.ncbi.nlm.nih.gov/pubmed/34198928
http://dx.doi.org/10.3390/ph14060542
work_keys_str_mv AT elawaadehab broadspectrumanticanceractivityandpharmacokineticpropertiesofaprenyloxysubstitutedindeno12bindolederivativediscoveredasck2inhibitor
AT birusrobin broadspectrumanticanceractivityandpharmacokineticpropertiesofaprenyloxysubstitutedindeno12bindolederivativediscoveredasck2inhibitor
AT marminonchristelle broadspectrumanticanceractivityandpharmacokineticpropertiesofaprenyloxysubstitutedindeno12bindolederivativediscoveredasck2inhibitor
AT bouazizzouhair broadspectrumanticanceractivityandpharmacokineticpropertiesofaprenyloxysubstitutedindeno12bindolederivativediscoveredasck2inhibitor
AT ballentinlaurens broadspectrumanticanceractivityandpharmacokineticpropertiesofaprenyloxysubstitutedindeno12bindolederivativediscoveredasck2inhibitor
AT aicheledagmar broadspectrumanticanceractivityandpharmacokineticpropertiesofaprenyloxysubstitutedindeno12bindolederivativediscoveredasck2inhibitor
AT leborgnemarc broadspectrumanticanceractivityandpharmacokineticpropertiesofaprenyloxysubstitutedindeno12bindolederivativediscoveredasck2inhibitor
AT josejoachim broadspectrumanticanceractivityandpharmacokineticpropertiesofaprenyloxysubstitutedindeno12bindolederivativediscoveredasck2inhibitor